Cargando…

Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer

PURPOSE: In this single institution retrospective study of patients with stage I medically inoperable non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR) we attempt to model overall survival (OS) using initial prognostic variables with specific attention on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmes, Oliver Edwin, MacRae, Robert, Cook, Graham, Cross, Peter, Nair, Vimoj, Marginean, Horia, Pantarotto, Jason R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833901/
https://www.ncbi.nlm.nih.gov/pubmed/29594215
http://dx.doi.org/10.1016/j.ctro.2017.07.001
_version_ 1783303562767368192
author Holmes, Oliver Edwin
MacRae, Robert
Cook, Graham
Cross, Peter
Nair, Vimoj
Marginean, Horia
Pantarotto, Jason R.
author_facet Holmes, Oliver Edwin
MacRae, Robert
Cook, Graham
Cross, Peter
Nair, Vimoj
Marginean, Horia
Pantarotto, Jason R.
author_sort Holmes, Oliver Edwin
collection PubMed
description PURPOSE: In this single institution retrospective study of patients with stage I medically inoperable non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR) we attempt to model overall survival (OS) using initial prognostic variables with specific attention on the Charlson co-morbidity index (CCI). METHODS: Between 2008 and 2013, 335 patients with medically inoperable stage I NSCLC were treated with SABR or hypofractionated radiotherapy (50–60 Gy in at least 5 Gy or 4 Gy fractions respectively) at our institution. Medical comorbidities and Charlson scores were determined by individual chart review. Patients were stratified into 3 groups based on the CCI score (0–1, 2–3, 4–9) and again based on the age-adjusted Charlson Comorbidity score (aCCI). Cumulative survival for each stratum was determined using the Kaplan-Meier method. Non-significant and confounding variables were identified and discounted from survival modeling. 3 sex stratified Cox regression models were tested: (1) aCCI with age and comorbidity combined; (2) age and CCI; (3) age alone, comorbidity removed. RESULTS: The median survival was 4.4 years and the median follow up 4.7 years. The median CCI and aCCI scores were 2 and 5 respectively. Patients with aCCI 7–12 had an increased hazard of death on univariate analysis HR 2.45 (1.15–5.22 95%CI, p = 0.02) and -excluding age as a competing variable- on multivariate analysis HR 2.25 (1.04–4.84 95%CI, p = 0.04). Patients with CCI 4-9 had an increased hazard of death on univariate analysis HR 1.57(1.30–2.90) but not on multivariate analysis. On formalized testing – with either continuous or categorical variables- all three survival models yielded similar coefficients of effect. CONCLUSION: We identify male gender, weight loss greater than 10% and age as independent prognostic factors for patients treated with medically inoperable NSCLC treated with SABR or hypofractionated radiotherapy. Based on our survival models, age alone can be used interchangeably with aCCI or CCI plus age with the same prognostic value. Age is more reliably recorded, less prone to error and therefore a more useful metric than Charlson score in this group of patients.
format Online
Article
Text
id pubmed-5833901
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58339012018-03-28 Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer Holmes, Oliver Edwin MacRae, Robert Cook, Graham Cross, Peter Nair, Vimoj Marginean, Horia Pantarotto, Jason R. Clin Transl Radiat Oncol Article PURPOSE: In this single institution retrospective study of patients with stage I medically inoperable non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR) we attempt to model overall survival (OS) using initial prognostic variables with specific attention on the Charlson co-morbidity index (CCI). METHODS: Between 2008 and 2013, 335 patients with medically inoperable stage I NSCLC were treated with SABR or hypofractionated radiotherapy (50–60 Gy in at least 5 Gy or 4 Gy fractions respectively) at our institution. Medical comorbidities and Charlson scores were determined by individual chart review. Patients were stratified into 3 groups based on the CCI score (0–1, 2–3, 4–9) and again based on the age-adjusted Charlson Comorbidity score (aCCI). Cumulative survival for each stratum was determined using the Kaplan-Meier method. Non-significant and confounding variables were identified and discounted from survival modeling. 3 sex stratified Cox regression models were tested: (1) aCCI with age and comorbidity combined; (2) age and CCI; (3) age alone, comorbidity removed. RESULTS: The median survival was 4.4 years and the median follow up 4.7 years. The median CCI and aCCI scores were 2 and 5 respectively. Patients with aCCI 7–12 had an increased hazard of death on univariate analysis HR 2.45 (1.15–5.22 95%CI, p = 0.02) and -excluding age as a competing variable- on multivariate analysis HR 2.25 (1.04–4.84 95%CI, p = 0.04). Patients with CCI 4-9 had an increased hazard of death on univariate analysis HR 1.57(1.30–2.90) but not on multivariate analysis. On formalized testing – with either continuous or categorical variables- all three survival models yielded similar coefficients of effect. CONCLUSION: We identify male gender, weight loss greater than 10% and age as independent prognostic factors for patients treated with medically inoperable NSCLC treated with SABR or hypofractionated radiotherapy. Based on our survival models, age alone can be used interchangeably with aCCI or CCI plus age with the same prognostic value. Age is more reliably recorded, less prone to error and therefore a more useful metric than Charlson score in this group of patients. Elsevier 2017-08-02 /pmc/articles/PMC5833901/ /pubmed/29594215 http://dx.doi.org/10.1016/j.ctro.2017.07.001 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Holmes, Oliver Edwin
MacRae, Robert
Cook, Graham
Cross, Peter
Nair, Vimoj
Marginean, Horia
Pantarotto, Jason R.
Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer
title Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer
title_full Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer
title_fullStr Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer
title_full_unstemmed Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer
title_short Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer
title_sort age-not charlson co-morbidity index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage i non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833901/
https://www.ncbi.nlm.nih.gov/pubmed/29594215
http://dx.doi.org/10.1016/j.ctro.2017.07.001
work_keys_str_mv AT holmesoliveredwin agenotcharlsoncomorbidityindexpredictsformortalityafterstereotacticablativeradiotherapyformedicallyinoperablestageinonsmallcelllungcancer
AT macraerobert agenotcharlsoncomorbidityindexpredictsformortalityafterstereotacticablativeradiotherapyformedicallyinoperablestageinonsmallcelllungcancer
AT cookgraham agenotcharlsoncomorbidityindexpredictsformortalityafterstereotacticablativeradiotherapyformedicallyinoperablestageinonsmallcelllungcancer
AT crosspeter agenotcharlsoncomorbidityindexpredictsformortalityafterstereotacticablativeradiotherapyformedicallyinoperablestageinonsmallcelllungcancer
AT nairvimoj agenotcharlsoncomorbidityindexpredictsformortalityafterstereotacticablativeradiotherapyformedicallyinoperablestageinonsmallcelllungcancer
AT margineanhoria agenotcharlsoncomorbidityindexpredictsformortalityafterstereotacticablativeradiotherapyformedicallyinoperablestageinonsmallcelllungcancer
AT pantarottojasonr agenotcharlsoncomorbidityindexpredictsformortalityafterstereotacticablativeradiotherapyformedicallyinoperablestageinonsmallcelllungcancer